Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 360293 | Other Identifier | IRAS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Liverpool Heart and Chest Hospital NHS Foundation Trust | OTHER |
Not provided
Not provided
Not provided
Not provided
This project aims to bridge the gap between technology and healthcare by developing a biofeedback intervention that enables daily monitoring of atrial fibrillation episodes and physical activity levels. The main question it aims to answer is:
Is a co-designed, usability-tested, bio-feedback intervention aimed at nudging patients with paroxysmal atrial fibrillation to increase physical activity feasible for a larger randomised control trial?
The trial is split into two separate phases, each adopting different study designs, data collection, and data analysis methods.
Phase 1 Co-design and usability testing:
In this phase, we aim to test if smartwatches can be used to monitor AF and physical activity so that personalised atrial fibrillation-specific summaries can be created and sent to participants as text message nudges. The aim is to encourage participants to be more physically active.
Participants will wear a smartwatch for 3 weeks, during which they will receive text messages giving them feedback on their atrial fibrillation and physical activity. After the 3 weeks, all participants will take part in a workshop to provide feedback on what they thought and what could be improved. Improvements will be implemented by the researchers, and the process will repeat for a total of two iterations. On the first iteration only, participants will also be asked to wear a Holter monitor OR chest strap and an additional smartwatch for the first 24 hours, alongside an accelerometer watch for the first 7 days.
Phase 2 Feasibility study with embedded process evaluation:
This phase aims to assess whether it is feasible and acceptable to run a larger trial across the UK (i.e. can the intervention be delivered properly and do patients think it is useful).
Participants will be randomly allocated to either their normal standard of care, or to receive a smartwatch with the biofeedback messaging service in addition to their normal standard of care. The study will take 6 and a half months in total. Both groups will complete online questionnaires periodically over this period. Both groups will also need to wear a smartwatch and accelerometer watch for 7 days before and after testing.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1- Biofeedback intervention + standard care | Experimental | If allocated to the intervention group, you will be sent a smartwatch and device introduction pack with information on how to download a custom mobile application named Motivate-cloud and the Polar Flow mobile application, with instructions on how to sync your Polar device. Once set up, you will wear the smartwatch device for 6-months that records heart rate and physical activity. During this time, you will be sent regular text messages with motivating information on your activity (steps, time sitting, standing and moving) and AF. *Important note: when we send you messages regarding your risk of AF, this is based on your heart rate variability (i.e. the variation in time between heart beats), and based on this variation, we predict we can determine whether the risk of being in AF has gone up or down for a given period of time.* |
|
| Group 2: Standard care | No Intervention | You would have had a conversation about the benefits of lifestyle and physical activity with your direct health care team prior to agreeing to receiving contact with the research team. If you are allocated to this group, you will continue with usual medical treatment for your atrial fribrillation as determined by your healthcare team. You will receive adequate information and support, lifestyle advice about smoking, exercise, diet, and weight control. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biofeedback intervention | Behavioral | Participants wearing a smartwatch will receive feedback on their paroxysmal atrial fibrillation and physical activity. This feedback will hopefully nudge them to become more physically active. |
| Measure | Description | Time Frame |
|---|---|---|
| Phase 1: Co-design biofeedback nudges and report content, layout and the optimal time/frequency of nudges. Underpinned by a double diamond framework, through an iterative co-design process. | 1) Patients' qualitative data (workshops and/or 1:1 feedback meetings) investigating nudges and report: A) Content B) Layout C) Delivery Intervals | Immediately after the 3-week usability testing iterations. |
| Phase 1: Co-design biofeedback nudges and report content, layout and the optimal time/frequency of nudges. Underpinned by a double diamond framework, through an iterative co-design process. | 2) Participants' reflection/feedback via user diaries. | During each 3-week usability testing period. |
| Phase 2: Determine the number of patients identified, screened, appraoched eligable, consented, completed the trial, withdrew from the trial, and adherence to the trial. | Outcome measure: Information will be collected on:
| Through study recruitment and all data collection, an average of 2 years. |
| Measure | Description | Time Frame |
|---|---|---|
| Phase 1: Receive feedback on the usability and acceptability of the biofeedback intervention | 1) Multidisciplinary stakeholder groups including the research team and patients' qualitative data (workshops and/or 1:1 feedback meetings) investigating: A) General usability and acceptability. B) Faults or problem identification. C) Intervention delivery optimisation. | Immediately after the 3-week usability testing iterations |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Luca J Howard | Contact | + 151 231 2121 | l.j.howard@ljmu.ac.uk | |
| Benjamin Buckley | Contact | 0151 231 2121 | B.J.Buckley@ljmu.ac.uk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Liverpool John Moores University | Recruiting | Liverpool | Merseyside | L3 3AF | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Phase 1: Receive feedback on the usability and acceptability of the biofeedback intervention | 2) Participants reflection / feedback via user diaries. | During each 3-week usability testing period. |
| Phase 1: Receive feedback on the usability and acceptability of the biofeedback intervention | 3) Researcher observations | Through study recruitment and data collection, an average of 4 months |
| Phase 1: Receive feedback on the usability and acceptability of the biofeedback intervention | 4) Systems usability scale (SUS) questionnaire during the first co-design workshop. Scored from 0-100. Higher score = better usability (outcome). | Immediately after the first 3-week usability testing iteration. |
| Phase 1: Quantify the time taken and resources required to produce nudges to gain an understanding of the maximum potential active intervention participants that can be simultaneously ongoing in Phase-2 feasibility RCT | Information will be collected on: 1) The average time taken to produce each nudge (measured from accessing patient account to sending item). A) Any identified issues with the intervention (via researcher diary). | Through study recruitment and data collection, an average of 4 months |
| Phase 1: Investigate the validity and quantify the error of the Polar Pacer smartwatch HRV data against a clinical-grade Holter monitor, or the Polar H10 chest strap. | 1) Continuous HRV data from both devices simultaneously to evaluate: A) Validity and reliability of the Polar Pacer HRV data. B) Error associated with Polar Pacer HRV data. C) Measurement error at each MET threshold. D) Optimal MET threshold cut off for HRV (risk of AF) analysis. E) Considerations for any future validation studies. | First 24-hour periprocedural period. |
| Phase 1: Investigate the reliability and quantify the error of the Polar Pacer activity score as a measurement of PA against the GENEactiv wrist-based accelerometer | 1) Simultaneous collection of accelerometer and PA data from both devices to evaluate: A) Reliability of the Polar Pacer activity score as a measure of PA. B) PA measurement error of the Polar Pacer. C) Considerations for any future validation studies. | First 7-days of periprocedural period. |
| Phase 2: 2) Evaluate the acceptability of the intervention to patients, assessing the feasibility of delivering the biofeedback intervention to patients with paroxysmal AF | Qualitative acceptability assessment through topic-guided semi-structured 1:1 interviews post-intervention, investigating:
| Within 1 month of completing all 6-month post-intervention data collection. |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 1.1) Physical activity (steps) measured via Polar Pacer smartwatch and GENEactiv wrist-based accelerometer. | 7-days pre and 7-days post intervention. (*Intervention group only*: Polar Pacer steps additionally measured throughout 6-month intervention). |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 1.2) Physical activity (time spent sleeping) measured via Polar Pacer smartwatch and GENEactiv wrist-based accelerometer. | 7-days pre and 7-days post intervention. (*Intervention group only*: Polar Pacer time spent sleeping additionally measured throughout 6-month intervention). |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 1.3) Physical activity (time spent sitting) measured via Polar Pacer smartwatch and GENEactiv wrist-based accelerometer. | 7-days pre and 7-days post intervention. (*Intervention group only*: Polar Pacer time spent sitting additionally measured throughout 6-month intervention). |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 1.4) Physical activity (time spent standing) measured via Polar Pacer smartwatch and GENEactiv wrist-based accelerometer. | 7-days pre and 7-days post intervention. (*Intervention group only*: Polar Pacer time spent standing additionally measured throughout 6-month intervention). |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 1.5) Physical activity (time spent in light activity) measured via Polar Pacer smartwatch and GENEactiv wrist-based accelerometer. | 7-days pre and 7-days post intervention. (*Intervention group only*: Polar Pacer time spent in light activity additionally measured throughout 6-month intervention). |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 1.6) Physical activity (time spent in moderate activity) measured via Polar Pacer smartwatch and GENEactiv wrist-based accelerometer. | 7-days pre and 7-days post intervention. (*Intervention group only*: Polar Pacer time spent in moderate activity additionally measured throughout 6-month intervention). |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 1.7) Physical activity (time spent in vigorous activity) measured via Polar Pacer smartwatch and GENEactiv wrist-based accelerometer. | 7-days pre and 7-days post intervention. (*Intervention group only*: Polar Pacer time spent in vigorous activity additionally measured throughout 6-month intervention). |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 1.8) Physical activity (calories) measured via Polar Pacer smartwatch | 7-days pre and 7-days post intervention. (*Intervention group only*: Polar Pacer calories additionally measured throughout 6-month intervention). |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 1.9) Physical activity (total METs) measured via Polar Pacer smartwatch. | 7-days pre and 7-days post intervention. (*Intervention group only*: Polar Pacer total METs additionally measured throughout 6-month intervention). |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 2) Health-related quality of life via the AF Effect on quality of life (AFEQT) scale. Scored from 0-100. Higher score = best possible quality of life. | 4 timepoints: Baseline (pre-intervention), month-1, month-3 and month-6 (post-intervention) |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 3) EuroQol, 5 Dimensions, 5 Levels of severity (EQ-5D-5L) questionnaire. Responses are combined into a 5-digit code, ranging from 11111 (perfect health) to 55555 (worst health). This 5-digit code is converted into a weighted index score that represents the societal value of that health state. A score of 1.000 represents full health. | 4 timepoints: Baseline (pre-intervention), month-1, month-3 and month-6 (post-intervention) |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 4) 12-Item Short Form Survey (SF-12). Measures physical and mental components of health, with each question carrying a different weighting. Norm-based scoring is used, allowing comparison to the general US population. A score of 50 is considered average health, with higher values indicating better health. | 4 timepoints: Baseline (pre-intervention), month-1, month-3 and month-6 (post-intervention) |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 5) AF symptom severity via the University of Toronto Atrial Fibrillation Symptom Severity (AFSS) questionnaire. Scores range from 0-35. Higher score indicate more severe symptoms. | 4 timepoints: Baseline (pre-intervention), month-1, month-3 and month-6 (post-intervention) |
| Phase 2: Assess the suitability of outcome measures for future full-scale RCT. | 6) HRV (risk of AF) measured as % time with a risk of AF and number of episodes. | 7-days pre and 7-days post intervention. (*Intervention group only*: Polar Pacer HRV additionally measured throughout 6-month intervention). |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |